Picture of Palatin Technologies logo

PTN Palatin Technologies Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m+23.67%
3m-51.18%
6m-34.91%
1yr-41.78%
Volume Change (%)
10d/3m+159.21%
Price vs... (%)
52w High-67.43%
50d MA-18.86%
200d MA-22.44%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-978.99%
Return on Equity-1246.7%
Operating Margin-324.83%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Palatin Technologies EPS forecast chart

Profile Summary

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. It has completed Phase III PL9643 clinical study for dry eye disease. It is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.

Directors

Last Annual
June 30th, 2023
Last Interim
December 31st, 2023
Incorporated
November 21st, 1986
Public Since
December 21st, 1999
No. of Shareholders
90
No. of Employees
34
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNYSE MKT
Shares in Issue
16,136,640

PTN Share Price Performance

Upcoming Events for PTN

Q3 2024 Palatin Technologies Inc Earnings Release

Palatin Technologies Inc Annual Shareholders Meeting

Q4 2024 Palatin Technologies Inc Earnings Release

Similar to PTN

FAQ